<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00397800</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000515982</org_study_id>
    <secondary_id>KRDI-TUM-R-F-015-V-0030-I</secondary_id>
    <secondary_id>EU-20633</secondary_id>
    <nct_id>NCT00397800</nct_id>
  </id_info>
  <brief_title>Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma</brief_title>
  <official_title>Safety and Efficacy of Sequential Treatment With a Combination of Rituximab, Fludarabine and Cyclophosphamide Followed by Zevalin (Rituximab and Y-Ibritumomab Tiuxetan) - A Phase I/II Study for Treatment of Patients With Relapsed Indolent and Transformed CD20-Positive B-Cell Non-Hodgkin's-Lymphoma Ineligible for High-Dose Chemo(Radio)Therapy Supported by Autologous Peripheral Blood Stem-Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität München</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität München</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different&#xD;
      ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and&#xD;
      help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such&#xD;
      as fludarabine and cyclophosphamide, work in different ways to stop the growth of cancer&#xD;
      cells, either by killing the cells or by stopping them from dividing. Radiolabeled monoclonal&#xD;
      antibodies, such as yttrium Y 90 ibritumomab tiuxetan, can find cancer cells and carry&#xD;
      cancer-killing substances to them without harming normal cells. Giving rituximab and&#xD;
      chemotherapy together with yttrium Y 90 ibritumomab tiuxetan may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This phase I/II trial is studying the side effects and best dose of yttrium Y 90&#xD;
      ibritumomab tiuxetan when given together with rituximab, fludarabine, and cyclophosphamide&#xD;
      and to see how well they work in treating patients with relapsed B-cell non-Hodgkin's&#xD;
      lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the dose-limiting toxicity and maximum tolerated dose of rituximab and yttrium&#xD;
           Y 90 (^90Y) ibritumomab tiuxetan when administered with rituximab as radioimmunotherapy&#xD;
           after rituximab, fludarabine, and cyclophosphamide in patients with relapsed indolent,&#xD;
           mantle cell, or transformed CD20-positive B-cell non-Hodgkin's lymphoma.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the overall survival in patients treated with this regimen.&#xD;
&#xD;
        -  Determine time to progression and event-free survival in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine partial and complete response rates in patients treated with this regimen.&#xD;
&#xD;
        -  Determine time to maximal response in patients treated with this regimen.&#xD;
&#xD;
        -  Determine response duration in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the feasibility of additional antineoplastic treatment following disease&#xD;
           relapse after treatment with rituximab and ^90Y ibritumomab tiuxetan in these patients.&#xD;
&#xD;
      OUTLINE: This is a prospective, nonrandomized, multicenter, phase I dose-escalation study of&#xD;
      yttrium Y 90 (^90Y) ibritumomab tiuxetan followed by a phase II open-label study.&#xD;
&#xD;
        -  Phase I:&#xD;
&#xD;
             -  Chemoimmunotherapy: Patients receive rituximab IV on day 1 and fludarabine IV over&#xD;
                30 minutes and cyclophosphamide IV over 60 minutes on days 1-3. Treatment repeats&#xD;
                every 4 weeks for up to 3 courses in the absence of disease progression. Four weeks&#xD;
                after the first day of the last chemoimmunotherapy course, patients receive 1 dose&#xD;
                of rituximab IV alone. Patients with disease progression are removed from the&#xD;
                study. Patients with stable disease proceed to radioimmunotherapy 8-12 weeks after&#xD;
                the first day of the last chemoimmunotherapy course.&#xD;
&#xD;
             -  Radioimmunotherapy: Patients receive rituximab IV and an imaging dose of indium In&#xD;
                III ibritumomab tiuxetan IV over 10 minutes on day 1. Patients then undergo&#xD;
                imaging. If dosimetry is acceptable, patients receive rituximab IV and ^90Y&#xD;
                ibritumomab tiuxetan IV over 10 minutes on day 8.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of ^90Y ibritumomab tiuxetan until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at&#xD;
      which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
        -  Phase II: Patients receive chemoimmunotherapy and radioimmunotherapy as in phase I, at&#xD;
           the MTD determined in phase I.&#xD;
&#xD;
      Treatment continues in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for up to 2 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 12 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2005</start_date>
  <completion_date type="Anticipated">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>yttrium Y 90 ibritumomab tiuxetan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed CD20-positive B-cell non-Hodgkin's lymphoma (NHL), including&#xD;
             any of the following subtypes:&#xD;
&#xD;
               -  Indolent NHL, including any of the following:&#xD;
&#xD;
                    -  Follicular&#xD;
&#xD;
                    -  Lymphoplasmacytoid&#xD;
&#xD;
                    -  Marginal zone&#xD;
&#xD;
               -  Mantle cell NHL&#xD;
&#xD;
               -  Transformed B-cell NHL&#xD;
&#xD;
          -  In at least first relapse with an indication for systemic antineoplastic treatment, as&#xD;
             defined by the following:&#xD;
&#xD;
               -  Local or constitutional (B-) symptoms&#xD;
&#xD;
               -  Hypersplenism due to splenic involvement&#xD;
&#xD;
               -  Bulky disease (&gt; 7.5 cm in diameter)&#xD;
&#xD;
               -  Impending medical problems derived from rapid disease progression within the past&#xD;
                  6 months, as defined by an observed or anticipated &gt; 50% increase in the sum of&#xD;
                  the areas calculated from multiplying the greatest perpendicular diameters of&#xD;
                  each lesion&#xD;
&#xD;
          -  Measurable lesions of lymphoma infiltration&#xD;
&#xD;
          -  Medically ineligible for high-dose treatment followed by autologous stem cell support&#xD;
&#xD;
          -  Adequate bone marrow cellularity (&gt; 15% of marrow area covered by hematopoiesis)&#xD;
&#xD;
          -  No CNS, leptomeningeal, spinal cord, or testes lymphoma involvement&#xD;
&#xD;
          -  No lymphoma lesion mandating emergency radiotherapy&#xD;
&#xD;
          -  No clinical, cytological, cytogenetic, or histopathologic indication of&#xD;
             myelodysplastic syndrome&#xD;
&#xD;
          -  If there is bone marrow infiltration detected prior to chemoimmunotherapy, patient&#xD;
             must undergo a repeat bone marrow biopsy prior to planned treatment with&#xD;
             radioimmunotherapy to verify the level of bone marrow infiltration is &lt; 25%&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,500/mm³&#xD;
&#xD;
          -  Platelet count &gt; 150,000/mm³&#xD;
&#xD;
          -  Hemoglobin &gt; 9 g/dL&#xD;
&#xD;
          -  Creatinine &lt; 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Bilirubin &lt; 2 times ULN&#xD;
&#xD;
          -  ALT and AST &lt; 2 times ULN&#xD;
&#xD;
          -  Albumin &gt; 2.5 g/dL&#xD;
&#xD;
          -  INR &lt; 1.5&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for ≥ 12 months after&#xD;
             completion of study treatment&#xD;
&#xD;
          -  No concurrent severe and/or uncontrolled medical disease that would preclude study&#xD;
             compliance, including any of the following:&#xD;
&#xD;
               -  Uncontrolled diabetes&#xD;
&#xD;
               -  Congestive heart failure&#xD;
&#xD;
               -  Chronic renal disease&#xD;
&#xD;
               -  Active uncontrolled infection&#xD;
&#xD;
          -  No bleeding risks or disorders, including any of the following:&#xD;
&#xD;
               -  CNS abnormalities suggesting an increased susceptibility for hemorrhage,&#xD;
                  including recent history of stroke as demonstrated by cranial contrast-enhanced&#xD;
                  CT scan&#xD;
&#xD;
               -  Severe arrhythmia or uncontrolled hypertension&#xD;
&#xD;
               -  Myocardial infarction within the past 6 months&#xD;
&#xD;
               -  Diabetic retinopathy with history of symptomatic hemorrhage&#xD;
&#xD;
               -  Known and potentially active gastrointestinal bleeding foci&#xD;
&#xD;
               -  Concurrent anticoagulant medication that must be continued even with platelet&#xD;
                  count &lt; 20,000/mm³ (e.g., following mitral valve replacement, anti-phospholipid&#xD;
                  syndrome, or recurrent venous thromboembolism)&#xD;
&#xD;
               -  Other congenital or acquired hemorrhagic diatheses&#xD;
&#xD;
          -  No ongoing autoimmune hemolytic anemia&#xD;
&#xD;
          -  No known presence of anti-murine antibody reactivity&#xD;
&#xD;
          -  No known hypersensitivity to murine or chimeric antibodies or proteins&#xD;
&#xD;
          -  No known HIV infection&#xD;
&#xD;
          -  No psychiatric illness that would preclude study requirements&#xD;
&#xD;
          -  No other malignant disorder within the past 10 years except basal cell carcinoma of&#xD;
             the skin or carcinoma in situ of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  No more than 4 prior systemic anti-lymphoma regimens (including single-agent&#xD;
             rituximab)&#xD;
&#xD;
          -  At least 2 months since prior systemic anti-lymphoma treatment (including single-agent&#xD;
             rituximab)&#xD;
&#xD;
          -  No prior radioimmunotherapy&#xD;
&#xD;
          -  No prior autologous or allogeneic hematopoietic stem cell transplantation&#xD;
&#xD;
          -  No prior treatment with purine analogues that has not resulted in remission for &gt; 1&#xD;
             year&#xD;
&#xD;
          -  No prior anti-CD20 radioimmunoconjugate therapy&#xD;
&#xD;
          -  More than 5 years since prior radiotherapy to extensive fields covering lymph node&#xD;
             regions on both sides of the diaphragm or &gt; 50% of the spinal column&#xD;
&#xD;
          -  More than 4 weeks since prior surgery&#xD;
&#xD;
          -  No concurrent oral anticoagulant therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Peschel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Technische Universität München</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizinische Klinik, Klinikum Augsburg</name>
      <address>
        <city>Augsburg</city>
        <zip>D-86156</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik III - Universitaetsklinikum Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>D-91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Goettingen</name>
      <address>
        <city>Goettingen</city>
        <zip>D-37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Schleswig-Holstein - Campus Luebeck</name>
      <address>
        <city>Luebeck</city>
        <zip>D-23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinkum Magdeburg der Otto-von-Guericke-Universitaet Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>D-39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>D-55101</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMU-Klinikum Grosshadern</name>
      <address>
        <city>Munich</city>
        <zip>D-81366</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Rechts Der Isar - Technische Universitaet Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>D-81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universitaet Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>D-93042</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center Ulm at Universitaetsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>D-89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik II - Universitaetsklinikum Wuerzburg</name>
      <address>
        <city>Wuerzburg</city>
        <zip>D-97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <study_first_submitted>November 9, 2006</study_first_submitted>
  <study_first_submitted_qc>November 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2006</study_first_posted>
  <last_update_submitted>August 27, 2012</last_update_submitted>
  <last_update_submitted_qc>August 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

